Cerus (NASDAQ:CERS) issued its earnings results on Thursday. The biotechnology company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01, Bloomberg Earnings reports. Cerus had a negative net margin of 139.06% and a negative return on equity of 154.10%. The business had revenue of $16.20 million for the quarter, compared to the consensus estimate of $17.53 million. During the same quarter last year, the firm posted ($0.13) EPS. The business’s revenue for the quarter was up 60.4% compared to the same quarter last year.
Shares of Cerus (NASDAQ CERS) opened at $4.87 on Friday. Cerus has a one year low of $1.93 and a one year high of $5.43. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11.
A number of equities analysts have recently commented on CERS shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $5.00 target price on shares of Cerus in a research note on Friday, January 5th. Zacks Investment Research downgraded shares of Cerus from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. BidaskClub raised shares of Cerus from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. BTIG Research reissued a “neutral” rating on shares of Cerus in a research note on Friday, December 8th. Finally, ValuEngine raised shares of Cerus from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Cerus has a consensus rating of “Hold” and an average price target of $5.00.
ILLEGAL ACTIVITY NOTICE: “Cerus (CERS) Posts Earnings Results, Beats Estimates By $0.01 EPS” was first posted by BBNS and is the property of of BBNS. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/2018/03/10/cerus-cers-posts-earnings-results-beats-estimates-by-0-01-eps/1998954.html.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.